Sildenafil Disrupts a Cholesterol Pathway Cancer Cells Need to Spread

Sildenafil, the molecule behind Viagra, has a new job description. In lab cells and mice, the drug gums up a cholesterol-handling step that metastatic cancer cells appear to need, a Weizmann Institute team reports in Cancer Research. A separate look at roughly five million Israeli health records then hints that cancer patients already on sildenafil survived longer than matched patients who were not.

The research is preclinical and observational: no prospective human trial has tested the idea. The senior author, cancer researcher Ayelet Erez, frames it as a reason to design that next study, not as a treatment. That register matters, because metastasis, the spread of cancer from where it started to a new organ, is what kills most cancer patients, even when the original tumor is under control.

The mechanism runs through a familiar drug target. Sildenafil inhibits phosphodiesterase type 5, or PDE5, an enzyme best known for relaxing blood vessels. Blocking PDE5 raises levels of cGMP, a small signaling molecule that helps blood vessels relax, which is how the drug treats erectile dysfunction and pulmonary hypertension. The Weizmann team found that elevated cGMP also jams a protein called NPC1 that hauls cholesterol around inside cells. NPC1 is the same protein whose loss-of-function mutations cause Niemann-Pick type C, a rare lysosomal storage disease, so its role in moving cholesterol inside cells is well established. Cancer cells on the move seem to need that cholesterol traffic; without it, their ability to invade new tissue drops in cell and mouse experiments.

The paper, "PDE5a Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking Through a Non-canonical cGMP-Dependent Pathway," appears in the [American Association for Cancer Research journal Cancer Research](https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-26-1818/786876/PDE5a-Inhibition-Restricts-Cancer-Metastasis-by). The team announced the work through the Weizmann Institute, where Erez's lab studies the tumor microenvironment.

The human side is a retrospective look, not a clinical trial. Researchers pulled records from Clalit Health Services, Israel's largest public healthcare provider, covering about five million patients. Among cancer patients in that database, those also taking sildenafil appeared to survive longer than matched cancer patients not on the drug, after adjusting for the usual confounders researchers can see in claims data. Retrospective studies can show association but not causation, and who gets prescribed sildenafil in the first place is a known confounder: the drug is prescribed for conditions that themselves correlate with health behaviors and access to care.

The finding is still a candidate. In vitro and mouse metastasis data do not always translate to humans, which is why a prospective clinical trial is the missing step. As of the paper's publication, no registered trial on ClinicalTrials.gov appears to test sildenafil specifically as an anti-metastatic therapy in cancer patients. The researchers' own language is that the work "could someday point to a novel means of tackling metastatic cancers," a register the study design justifies and the marketing around the drug does not.

The economic case is part of why a repurposing angle is interesting at all. Sildenafil went off patent years ago, costs pennies per pill, and has a safety profile documented across millions of prescriptions. A drug that is already cheap, generic, and well-characterized is a much faster starting point than a fresh small molecule, even before a trial begins.

For now, the watch item is straightforward: a registered, prospective trial of sildenafil in a defined cancer population, with metastasis, not the original tumor, as the endpoint. Until that trial is designed, enrolled, and read out, the cholesterol-trafficking mechanism is the news, and the brand-name frame is the noise.